Hai Yan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2159790/publications.pdf

Version: 2024-02-01

47 papers	18,243 citations	172457 29 h-index	243625 44 g-index
47 all docs	47 docs citations	47 times ranked	21982 citing authors

#	Article	IF	Citations
1	Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies. Clinical Cancer Research, 2021, 27, 383-388.	7.0	12
2	The implications of IDH mutations for cancer development and therapy. Nature Reviews Clinical Oncology, 2021, 18, 645-661.	27.6	155
3	Abstract 2103: Distinct methylation patterns correlate with unique clinical and genomic profiles of brainstem gliomas. , 2021, , .		1
4	TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist. Acta Neuropathologica Communications, 2021, 9, 178.	5.2	8
5	The integrated genomic and epigenomic landscape of brainstem glioma. Nature Communications, 2020, 11, 3077.	12.8	50
6	Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. Molecular Cancer Research, 2020, 18, 968-980.	3.4	18
7	The potential of cerebrospinal fluidâ€“based liquid biopsy approaches in CNS tumors. Neuro-Oncology, 2019, 21, 1509-1518.	1.2	46
8	Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe. Nanotechnology, 2019, 30, 275101.	2.6	21
9	CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP. Molecular Cancer Research, 2019, 17, 2042-2050.	3.4	15
10	Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. Acta Neuropathologica, 2019, 137, 297-306.	7.7	109
11	Sensitive and rapid detection ofTERTpromoter andIDHmutations in diffuse gliomas. Neuro-Oncology, 2019, 21, 440-450.	1.2	27
12	Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 694-699.	2.2	18
13	Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis. Acta Neuropathologica, 2018, 135, 285-298.	7.7	10
14	Synthesis and Evaluation of a ¹⁸F-Labeled Triazinediamine Analogue for Imaging Mutant IDH1 Expression in Gliomas by PET. ACS Medicinal Chemistry Letters, 2018, 9, 606-611.	2.8	17
15	Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities. Cancer Research, 2018, 78, 36-50.	0.9	35
16	The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nature Communications, 2018, 9, 2087.	12.8	124
17	Biological Role and Therapeutic Potential of IDH Mutations in Cancer. Cancer Cell, 2018, 34, 186-195.	16.8	234
18	Improved grading of IDH-mutated astrocytic gliomas. Nature Reviews Neurology, 2018, 14, 383-384.	10.1	2

#	Article	IF	Citations
19	Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. Molecular Cancer Research, 2017, 15, 507-520.	3.4	41
20	Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors. Oncotarget, 2017, 8, 76644-76655.	1.8	27
21	Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. European Journal of Medicinal Chemistry, 2016, 119, 218-230.	5.5	13
22	Isocitrate dehydrogenase mutations in gliomas. Neuro-Oncology, 2016, 18, 16-26.	1.2	221
23	The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. Human Pathology, 2015, 46, 1626-1632.	2.0	88
24	The genetic landscape of anaplastic astrocytoma. Oncotarget, 2014, 5, 1452-1457.	1.8	69
25	Cancer-associated Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation and d-2-Hydroxyglutarate Stimulate Glutamine Metabolism under Hypoxia. Journal of Biological Chemistry, 2014, 289, 23318-23328.	3.4	81
26	Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nature Genetics, 2014, 46, 726-730.	21.4	148
27	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget, 2014, 5, 1515-1525.	1.8	237
28	TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6021-6026.	7.1	1,202
29	Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas. Cancer Research, 2013, 73, 496-501.	0.9	108
30	A heterozygous IDH1^{R132H/WT} mutation induces genome-wide alterations in DNA methylation. Genome Research, 2012, 22, 2339-2355.	5.5	157
31	Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature, 2012, 483, 484-488.	27.8	630
32	Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget, 2012, 3, 709-722.	1.8	532
33	2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations. PLoS ONE, 2011, 6, e16812.	2.5	100
34	Genomic alterations and the pathogenesis of glioblastoma. Cell Cycle, 2011, 10, 1174-1175.	2.6	4
35	Altered Telomeres in Tumors with ATRX and DAXX Mutations. Science, 2011, 333, 425-425.	12.6	891
36	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3270-3275.	7.1	390

#	Article	IF	Citations
37	HDMX regulates p53 activity and confers chemoresistance to 3-Bis(2-chloroethyl)-1-nitrosourea. Neuro-Oncology, 2010, 12, 956-966.	1.2	11
38	Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget, 2010, 1, 265-277.	1.8	96
39	Mutant Metabolic Enzymes Are at the Origin of Gliomas. Cancer Research, 2009, 69, 9157-9159.	0.9	132
40	IDH1andIDH2Mutations in Gliomas. New England Journal of Medicine, 2009, 360, 765-773.	27.0	5,285
41	An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science, 2008, 321, 1807-1812.	12.6	5,230
42	Snapshot of the Allele-Specific Variation in Human Gene Expression. , 2005, 311, 031-038.		1
43	Allelic variations in gene expression. Current Opinion in Oncology, 2004, 16, 39-43.	2.4	50
44	Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8817-8822.	7.1	744
45	Allelic Variation in Human Gene Expression. Science, 2002, 297, 1143-1143.	12.6	618
46	Small changes in expression affect predisposition to tumorigenesis. Nature Genetics, 2002, 30, 25-26.	21.4	234
47	Genetics of glioma. , 0, , 1-23.		1